KOLON LIFE SCIENCE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22,050 KRW | -3.50% |
|
-0.68% | -14.20% |
| Sales 2022 | 192B 140M 191M | Sales 2023 | 125B 90.49M 124M | Capitalization | 293B 213M 291M |
|---|---|---|---|---|---|
| Net income 2022 | 2.13B 1.55M 2.11M | Net income 2023 | -30.73B -22.31M -30.45M | EV / Sales 2022 | 1.98 x |
| Net Debt 2022 | 67.54B 49.04M 66.94M | Net Debt 2023 | 100B 72.82M 99.4M | EV / Sales 2023 | 3.16 x |
| P/E ratio 2022 |
162
x | P/E ratio 2023 |
-9.55
x | Employees | 421 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.03% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.50% | ||
| 1 week | -0.68% | ||
| Current month | -3.50% | ||
| 1 month | -3.71% | ||
| 3 months | -21.25% | ||
| 6 months | -19.53% | ||
| Current year | -14.20% |
1 week
21 900.00
23 250.00
1 month
21 500.0023 600.00
Current year
20 000.0031 000.00
1 year
20 000.0034 950.00
3 years
20 000.0050 600.00
5 years
11 000.0052 000.00
10 years
11 000.00200 266.67
| Managers | Title | Age | Since |
|---|---|---|---|
Woo-Seok Lee
CEO | Chief Executive Officer | 67 | 11-12-31 |
Ji-Yeon Han
CMP | Compliance Officer | - | - |
Soo-Jeong Kim
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Woo-Seok Lee
CEO | Chief Executive Officer | 67 | 11-12-31 |
Chan-Hee Lee
BRD | Director/Board Member | 67 | 17-03-23 |
Young-Wu Jo
BRD | Director/Board Member | 57 | 16-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 22,050 | -3.50% | 12,448 |
| 24-04-25 | 22,850 | 0.00% | 16,675 |
| 24-04-24 | 22,850 | -0.22% | 5,850 |
| 24-04-23 | 22,900 | +3.15% | 30,429 |
| 24-04-22 | 22,200 | 0.00% | 4,091 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
KOLON LIFE SCIENCE Inc. is a Korea-based company mainly engaged in the manufacturing of functional materials. The Company operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.20% | 183M | |
| +26.31% | 661B | |
| +27.19% | 566B | |
| -6.58% | 352B | |
| +21.00% | 332B | |
| +3.43% | 283B | |
| +14.60% | 231B | |
| +5.22% | 200B | |
| -9.04% | 195B | |
| -6.11% | 145B |
- Stock Market
- Equities
- A102940 Stock
